Swiss National Bank raised its stake in TESARO Inc (NASDAQ:TSRO) by 1.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 138,600 shares of the biopharmaceutical company’s stock after buying an additional 1,600 shares during the quarter. Swiss National Bank owned about 255,813.95% of TESARO worth $17,893,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Greenwood Capital Associates LLC raised its position in TESARO by 46.8% during the third quarter. Greenwood Capital Associates LLC now owns 2,781 shares of the biopharmaceutical company’s stock worth $359,000 after acquiring an additional 886 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of TESARO by 10.7% in the third quarter. Principal Financial Group Inc. now owns 26,233 shares of the biopharmaceutical company’s stock valued at $3,387,000 after acquiring an additional 2,541 shares in the last quarter. Daiwa Securities Group Inc. grew its stake in shares of TESARO by 16.1% in the third quarter. Daiwa Securities Group Inc. now owns 22,209 shares of the biopharmaceutical company’s stock valued at $2,867,000 after acquiring an additional 3,084 shares in the last quarter. Prudential Financial Inc. grew its stake in shares of TESARO by 2,290.4% in the third quarter. Prudential Financial Inc. now owns 39,680 shares of the biopharmaceutical company’s stock valued at $5,123,000 after acquiring an additional 38,020 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in shares of TESARO by 50.9% in the third quarter. American Century Companies Inc. now owns 5,826 shares of the biopharmaceutical company’s stock valued at $752,000 after acquiring an additional 1,965 shares in the last quarter.
TSRO has been the topic of a number of analyst reports. Citigroup reiterated a “buy” rating and set a $216.00 price objective on shares of TESARO in a research note on Monday, September 11th. Robert W. Baird reissued a “neutral” rating and issued a $140.00 target price (down previously from $155.00) on shares of TESARO in a report on Thursday, August 10th. Jefferies Group reissued a “hold” rating and issued a $124.00 target price on shares of TESARO in a report on Friday, November 3rd. Credit Suisse Group set a $190.00 target price on shares of TESARO and gave the stock a “buy” rating in a report on Friday, August 18th. Finally, HC Wainwright reiterated a “buy” rating on shares of TESARO in a report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. TESARO currently has an average rating of “Buy” and an average target price of $159.39.
In other news, VP Edward C. English sold 10,862 shares of the business’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total transaction of $1,465,501.04. Following the completion of the transaction, the vice president now owns 6,258 shares of the company’s stock, valued at $844,329.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Martin H. Jr. Huber sold 592 shares of the business’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $118.60, for a total value of $70,211.20. Following the transaction, the senior vice president now directly owns 6,943 shares of the company’s stock, valued at approximately $823,439.80. The disclosure for this sale can be found here. Insiders have sold a total of 21,525 shares of company stock valued at $2,716,431 in the last ninety days. Insiders own 34.60% of the company’s stock.
Shares of TESARO Inc (NASDAQ:TSRO) traded up $1.28 during trading on Monday, reaching $86.44. The company had a trading volume of 855,033 shares, compared to its average volume of 1,023,991. TESARO Inc has a fifty-two week low of $79.03 and a fifty-two week high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.16) by $0.69. The business had revenue of $142.77 million for the quarter, compared to analysts’ expectations of $130.57 million. TESARO had a negative return on equity of 93.39% and a negative net margin of 251.22%. The firm’s quarterly revenue was up 740.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.72) EPS. sell-side analysts forecast that TESARO Inc will post -8.16 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2017/12/04/swiss-national-bank-purchases-1600-shares-of-tesaro-inc-tsro.html.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.